Piero D. Dalerba, MD (Damon Runyon-Rachleff Innovator ‘16-‘17), of Columbia University Medical Center, New York, and colleagues, have identified a biomarker, the CDX2 gene, that could be used to predict which stage II colon cancer patients may benefit from chemotherapy after surgery to prevent a recurrence of their disease. They found that cancers that do not express the gene have a worse prognosis than those that do. The study was published in the online edition of the New England Journal of Medicine.